THJ-018

THJ-018 is a synthetic cannabinoid in the indazole-carboxamide family. It is the indazole analogue of JWH-018 and was identified in drug-monitoring systems in 2014. THJ-018 has been detected in herbal smoking products and forensic samples. Human hepatocyte studies have characterised its metabolism, but the clinical evidence remains limited and is often complicated by exposure to other synthetic cannabinoids.

Chemistry and identification

THJ-018 is (1-pentyl-1H-indazol-3-yl)(naphthalen-1-yl)methanone. It retains the naphthoyl group and N-pentyl side chain of JWH-018, but the indole core is replaced by an indazole. This makes it structurally distinct from JWH-018, despite their similar names and shared naphthoyl motif.

THJ-018 was identified alongside THJ-2201 in 2014. The latter is its 5-fluoropentyl analogue. Both compounds were reported in forensic monitoring, and THJ-2201 was placed under Schedule I control in the United States in January 2015 following reports of adverse events (Diao and colleagues, 2016).

Pharmacology

THJ-018 is classified as a synthetic cannabinoid receptor agonist. Its indazole-naphthoyl structure is consistent with activity at CB₁ receptors, but the published human literature is more developed for its metabolism than for its receptor pharmacology. A detailed receptor profile should not be inferred solely from its relationship to JWH-018.

Metabolism

A 2016 study incubated THJ-018 in human hepatocytes and identified 13 metabolites. The main pathways involved hydroxylation of the N-pentyl chain, followed by further oxidation or glucuronidation. Dihydrodiol formation on the naphthalene portion was also observed. These metabolites provide analytical targets for laboratories investigating suspected exposure (Diao and colleagues, 2016).

Reported effects and clinical evidence

THJ-018 has been detected in herbal products and in toxicological investigations, sometimes alongside other synthetic cannabinoids. A case series involving synthetic cannabinoid intoxications included THJ-018 among the substances identified in seized products and patient samples, but co-exposure made it difficult to isolate the contribution of each compound (Analytically confirmed synthetic cannabinoid intoxications from the STRIDA project, 2017).

Reliable human evidence is too limited to define a characteristic THJ-018 experience. Symptoms reported across synthetic cannabinoid intoxications include agitation, confusion, altered consciousness, seizures and cardiovascular changes, but these are not symptoms established specifically for THJ-018.

Toxicity and research limitations

Human metabolism has been investigated in vitro, but controlled clinical pharmacology and long-term safety data remain limited. There is no established human toxic range or reliable concentration-toxicity relationship for THJ-018. Product composition and the presence of multiple active cannabinoids remain important limitations in forensic interpretation.

Related compounds

THJ-018 is related to THJ-2201, JWH-018 and AM-2201. It is the indazole analogue of JWH-018, while THJ-2201 carries a terminal fluorine on its N-alkyl chain.